Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's ( NVO ; OTCPK:NONOF ) shares have seen an significant decline in late 2024, due to "disappointing" trial results. According to CNBC , trial patients of the new weight loss drug CagriSema only managed to achieveGerman Buy-Hold-Check investor. With a master's degree in both industrial engineering and economics, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure: I/we have a beneficial long position in the shar ...